Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ligand Pharma (LGND) PT Raised to $237 at H.C. Wainwright
February 7, 2020 8:29 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Ligand Pharma (NASDAQ: LGND) to $237.00 (from $214.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, Ligand announced 4Q19 and 2019 financial results, posting GAAP EPS of ($0.43) and $33.13 per share, respectively, compared with our... More
Ligand Pharma (LGND) Tops Q4 EPS by 8c
February 6, 2020 4:05 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.71, $0.08 better than the analyst estimate of $0.63. Revenue for the quarter came in at $27 million versus the consensus estimate of $25.2 million.
Ligand made tremendous progress during 2019 in areas that will drive our future success, including new license agreements, outstanding revenue performance driven by record revenue for Captisol and Kyprolis royalties, expansion of our proprietary technology platforms and continued investment in internal programs, said John Higgins,... More
